top of page
First in class novel inhibitors targeting a central pathway in fibrosis and inflammation
Inosi is developing therapies to address fibrosis, a condition associated with many chronic diseases where tissue damage leads to scarring and a loss of organ function.
Inosi’s technology is based on collaborative research from the founding team at Monash University, the Monash Biomedicine Discovery Institute, and the Monash Institute of Pharmaceutical Sciences.
IP Group helped spin-out the company and provided seed investment.
Our Partners
Fibrosis is a global problem with high unmet need
45%
deaths linked to fibrosis
10%
of the population have a fibrotic condition
0
drugs able to reverse fibrosis
bottom of page